Friday, 29 October 2021

Australia's most trusted
source of pharma news

Friday, 29 October 2021

MSD closes in on Sanofi

Posted 23 September 2021 AM

While Sanofi's Libtayo was touted to potentially become the first PD-1 inhibitor approved for cervical cancer in Australia, new designations and determinations handed out by the TGA reveal MSD's Keytruda is closing in.

Keytruda has been approved in the US since 2018 for patients with recurrent or metastatic cervical cancer, although it had not been clear whether MSD would seek a similar indication locally until now.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read. If you don't have a password, just enter your email address and then click Login.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.